96992 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Sub-classes:ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES
#2NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF
#3C-TYPE NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES
#4CNP PRODRUGS WITH LARGE CARRIER MOIETIES
#5COMPOSITIONS AND METHODS FOR EXPRESSING THERAPEUTICS
#6CNP CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE
#7CNP PRODRUGS WITH LARGE CARRIER MOIETIES
#8MANP Analogues
#9LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF
#10C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
#11NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
#12CNP Variants and Conjugates Thereof
#13Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death
#14CNP PRODRUGS WITH LARGE CARRIER MOIETIES
#15NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF
#16Use of c-type natriuretic peptide variants to treat osteoarthritis
#17MANP analogues
#18Method for purifying long chain polypeptide
#19CNP prodrugs with large carrier moieties
#20BRAIN NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES
#21ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES
#22C-TYPE NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES
#23CNP PRODRUGS WITH LARGE CARRIER MOIETIES
#24GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE
#25Natriuretic peptide receptor 1 antibodies and methods of use
#26N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same
#27BNP (1-32) epitope and antibodies directed against said epitope
#28Antibodies recognizing genetic variants of NT-proBNP
#29MANP analogues
#30Use of C-type natriuretic peptide variants to treat osteoarthritis
#31Peptides with vasodilatory and/or diuretic functions
#32HANP-Fc-containing molecular conjugate
#33Methods to Treat Diseases with Protein, Peptide and Antigen Modification
#34CNP prodrugs with large carrier moieties
#35TREATING CARDIOVASCULAR OR RENAL DISEASES
#36COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF
#37Method of treating a vasculopathy in a human subject
#38STABILIZED BIOACTIVE PEPTIDES AND METHODS OF IDENTIFICATION, SYNTHESIS, AND USE
#39Methods and Reagents to Treat Tumor and Cancer
#40Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
#41Surface plasmon resonance approach to monitor protein-ligand interactions
#42Natriuretic polypeptides
#43Stabilizied bioactive peptides and methods of identification, synthesis and use
#44Variants of C-Type Natriuretic Peptide
#45BNP (1-32) epitope and antibodies directed against said epitope
#46ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment
#47Natriuretic polypeptides
#48Assessing renal structural alterations and outcomes
#49Nucleic acids encoding for chimeric natriuretic polypeptides with unique pharmacologic profiles
#50Method of treating skeletal dysplasias using vessel dilator
#51Chimeric natriuretic peptide compositions and methods of preparation
#52Glyco-modified atrial natriuretic peptide
#53Methods of treatment of heart dysfunctions using diuretic and natriuretic polypeptides
#54Method of increasing natriuretic activity by administering natriuretic polypeptides with unique pharmacologic profiles
#55Natriuretic polypeptides
#56NATRIURETIC PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION
#57Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
#58Treating cardiovascular or renal diseases
#59PROANP COMPOSITIONS AND METHODS FOR TREATING ACUTE HEART FAILURE
#60Treatment and Prevention of Gastrointestinal Syndrome
#61Hybrid polypeptides with selectable properties
#62Method of treatment of cardiovascular or renal conditions with natriuretic polypeptides with unique pharmacologic profiles
#63Prognosis and risk assessment in stroke patients by determining the level of marker peptides
#64Natriuretic polypeptides
#65Molecularly imprinted polymers having affinity for natriuretic peptides
#66Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
#67BNP-SP antibodies
#68Method of treating cardiac arrhythmia with long acting atrial natriuretic peptide(LA-ANP)
#69Natriuretic polypeptides for reducing restenosis
#70Method of treatment of renal dysfunctions with chimeric natriuretic peptides
#71Method for increasing natriuresis or diuresis by isoforms of brain natriuretic peptide
#72METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS
#73Variants of C-type natriuretic peptide
#74Hybrid polypeptides with selectable properties
#75Methods of treatment of heart failure with natriuretic peptides
#76Compositions comprising natriuretic peptides and methods of use thereof
#77LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF
#78Fusion Proteins Comprising Canine FC Portions
#79Stabilized bioactive peptides and methods of identification, synthesis, and use
#80NATRIURETIC POLYPEPTIDES HAVING MUTATIONS WITHIN THEIR DISULFIDE RINGS
#81NATRIURETIC ACTIVITIES
#82PROCESS FOR THE PRODUCTION OF PREFORMED CONJUGATES OF ALBUMIN AND A THERAPEUTIC AGENT
#83Method for the in vitro diagnosis of stroke
#84Chimeric natriuretic peptides without hypotensive inducing capability
#85Natriuretic polypeptides for reducing or preventing restenosis
#86PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES
#87Peptidic Constructs with Amino Acid Surrogates
#88NOVEL POLYPEPTIDES RELATED TO B-TYPE NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE
#89USE OF CARDIAC HORMONES TO ASSESS RISK OF CARDIOVASCULAR COMPLICATION FROM VOLUME OVERLOAD
#90NATRIURETIC PEPTIDE RELATED FRAGMENT IN CARDIOVASCULAR DISEASE
#91POLYMER CONJUGATES OF CD-NP PEPTIDES
#92Polymer conjugates of nesiritide peptides
#93Chimeric natriuretic polypeptides with unique pharmacologic profiles
#94NPR-B agonists
#95Methods of reducing toxicity and effects of cocaine by administering a butyrylcholinesterase (BChE)-albumin fusion protein
#96Variants of C-type natriuretic peptides
#97USE OF BETA-MELANOTROPIN AS A THERAPEUTIC AGENT, EG FOR THE TREATMENT OF AIDS OR ALZHEIMER
#98Method of Purifying a Peptide
#99Process for Preparing Cardiodilatin Fragments; Highly Purified Cardiodilatin Fragments and Intermediate Products for the Preparation of Same
#100NATRIURETIC FUSION PROTEINS
#101Polynucleotides encoding for fusion proteins with natriuresis activity
#102Peptide having an extending action for half-life of object peptide in plasma
#103Variants of C-type natriuretic peptide
#104USE OF CNP-22, ALONE OR IN COMBINATION WITH PHYSALEMIN, AS A THERAPEUTIC AGENT
#105NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF
#106THERAPEUTIC USES OF INTERMEDIN 47 AND 53 PEPTIDES
#107BNP(1-32) epitope and antibodies directed against said epitope
#108Use of Gonadorelin as a therapeutic agent
#109USE OF C-TYPE NATRIURETIC PEPTIDE, ALONE OR IN COMBINATION WITH NEUROPEPTIDE AF, AS A THERAPEUTIC AGENT
#110USE OF NEUROTROPHIC FACTOR FOR RETINAL CHOLINERGIC NEURONS (NFRCN) AND CHORIONIC GONADOTROPIN-BETA (109-145) AS THERAPEUTIC AGENTS
#111USE OF URODILATIN AS A THERAPEUTIC AGENT
#112Diuretic and natriuretic polypeptides lacking the blood pressure lowering property
#113USE OF A PEPTIDE AS A THERAPEUTIC AGENT
#114USE OF MELANIN CONCENTRATING HORMONE AND MET-ENKEPHALIN AS THERAPEUTIC AGENTS
#115Method of determining equine NT-proBNP
#116Cyclic natriuretic peptide constructs
#117DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE
#118METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS
#119Amide linkage cyclic natriuretic peptide constructs
#120Methods of screening using a natriuretic peptide receptor
#121Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
#122Methods of diagnosing acute cardiac disorders using BNP-SP
#123Chimeric natriuretic peptides
#124PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND DNA
#125Polypeptides with natriuresis activity
#126Linear and cyclic melanocortin receptor-specific peptidomimetics
#127Natriuretic polypeptides
#128Synthetic Gene for Enhanced Expression in E. Coli
#129ATRIAL NATRIURETIC PEPTIDE (ANP) SPLICE VARIANTS AND METHODS OF USING SAME
#130Bifunctional hormone having alpha-MSH activity and natriuretic peptide activity and uses thereof
#131Stabilized bioactive peptides and methods of identification, synthesis, and use
#132Glycosylated Probnp
#133High purity peptides
#134Oxidized Human Bnp
#135Bna Conjugates and Methods of Use
#136METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS
#137Albumin Fusion Proteins
#138Novel brain natriuretic peptide variants and methods of use thereof
#139CONJUGATE OF NATRIURETIC PEPTIDE AND ANTIBODY CONSTANT REGION
#140Materials and methods for treatment of respiratory allergic diseases
#141Specific antibodies for diagnosing heart failure
#142Isoforms of brain natriuretic peptide
#143Process for the production of preformed conjugates of albumin and a therapeutic agent
#144Cyclic natriuretic peptide constructs
#145Amino acid surrogates for peptidic constructs
#146Linear natriuretic peptide constructs
#147ANF fusion proteins
#148Method of detecting a subfraction of proBNP
#149Method of detecting a subfraction of proBNP
#150Hybrid polypeptides having glucose lowering activity
#151Materials and methods for treatment of allergic diseases
#152Natriuretic compounds, conjugates, and uses thereof
#153Immunoassays for brain natriuretic propeptide
#154Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
#155Methods for increasing the production of a recombinant polypeptide from a host cell
#156Method of detecting native proBNP
#157Method of detecting native proBNP
#158Stabilized bioactive peptides and methods of identification, synthesis, and use
#159Natriuretic compounds, conjugates, and uses thereof
#160Brain natriuretic peptide
#161Adenovirus vectors encoding brain natriuretic peptide
#162Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
#163Use of cardiac hormones to assess risk of cardiovascular complication from volume overload
#164Chimeric natriuretic peptides